- ranked # 14 on the list -
BELLEVILLE, ON, Oct. 28 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, is pleased to be named among the Top 50 Best Small and Medium Employers in Canada. Bioniche was ranked number 14 by its employees. Two years ago, the Company attained a 13th place ranking (the Company did not participate in the survey last year).
The rankings are primarily determined using the results from employee opinion surveys, where 18 key engagement drivers are detailed and analyzed. The evaluation process also includes the assessment of organization practices and perspectives from the leadership team. This year, more than 160 companies across Canada registered to participate in the study.
"We are proud to once again be selected one of the top small and medium employers in Canada by our employees." said Graeme McRae, Chairman, President & CEO of Bioniche Life Sciences Inc. "Our employees, who are also shareholders in the Company, are our greatest asset. We appreciate their ongoing support and dedication."
Becoming a Top Best Small and Medium Employer is a very detailed and competitive process. This national awards program recognizes top employers with between 50 and 399 employees. This study mirrors the renowned Best Employer in Canada initiative run by partner, Aon Hewitt; however, caters to smaller businesses. The 2011 list of the Best Small & Medium Employers in Canada will be published in Maclean's magazine, and La Presse newspaper.
The study is conducted by the Queen's Centre for Business Venturing, the Queen's University School of Business and Aon Hewitt.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 211 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. For more information, please visit href="http://www.bioniche.com/">www.Bioniche.com.
Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
SOURCE Bioniche Life Sciences Inc.